ES2173977T3 - Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer. - Google Patents

Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.

Info

Publication number
ES2173977T3
ES2173977T3 ES95936515T ES95936515T ES2173977T3 ES 2173977 T3 ES2173977 T3 ES 2173977T3 ES 95936515 T ES95936515 T ES 95936515T ES 95936515 T ES95936515 T ES 95936515T ES 2173977 T3 ES2173977 T3 ES 2173977T3
Authority
ES
Spain
Prior art keywords
alfa
alzheimer
disease
pct
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95936515T
Other languages
English (en)
Inventor
Roger E Markwell
Julie Hawkins
Carol W Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2173977T3 publication Critical patent/ES2173977T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

METODO PARA MEJORAR EL PROCESO DE LA PROTEINA DEL PRECURSOR AMILOIDE A LO LARGO DE UNA TRAYECTORIA NO AMILOIDOGENICA EN PACIENTES QUE SUFREN, O SON PROPENSOS A SUFRIR, LA ENFERMEDAD DE ALZHEIMER Y METODO PARA TRATAR O PREVENIR LA ENFERMEDAD DE ALZHEIMER MEDIANTE LA REDUCCION DE LA PRODUCCION {BE}A4 EN PACIENTES QUE SUFREN, O SON PROPENSOS A SUFRIR, LA ENFERMEDAD DE ALZHEIMER Y QUE SUPONE LA ADMINISTRACION AL PACIENTE DE UNA CANTIDAD NO TOXICA, EFECTIVA , DE UN COMPUESTO DE ACETONITRILO, EL USO DE LA COMPOSICION EN LA PREPARACION DE UN MEDICAMENTO PARA UTILIZAR EN EL METODO Y UNA COMPOSICION PARA UTILIZAR EN EL METODO.
ES95936515T 1994-10-25 1995-10-17 Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer. Expired - Lifetime ES2173977T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods

Publications (1)

Publication Number Publication Date
ES2173977T3 true ES2173977T3 (es) 2002-11-01

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95936515T Expired - Lifetime ES2173977T3 (es) 1994-10-25 1995-10-17 Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.

Country Status (22)

Country Link
US (1) US5891887A (es)
EP (1) EP0786998B1 (es)
JP (1) JPH10509697A (es)
KR (1) KR100393365B1 (es)
CN (1) CN1085529C (es)
AT (1) ATE214926T1 (es)
AU (1) AU698695B2 (es)
BG (1) BG101500A (es)
BR (1) BR9509433A (es)
CZ (1) CZ287370B6 (es)
DE (1) DE69526102T2 (es)
DK (1) DK0786998T3 (es)
ES (1) ES2173977T3 (es)
GB (1) GB9421472D0 (es)
HK (1) HK1002057A1 (es)
HU (1) HUT77007A (es)
NO (1) NO312055B1 (es)
NZ (1) NZ295155A (es)
PT (1) PT786998E (es)
SK (1) SK50497A3 (es)
WO (1) WO1996012486A1 (es)
ZA (1) ZA958946B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
CA2323177A1 (en) 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219636T3 (es) * 1989-04-13 2004-12-01 Beecham Group P.L.C. Nuevos compuestos.
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU698695B2 (en) 1998-11-05
DE69526102T2 (de) 2002-10-31
HUT77007A (hu) 1998-03-02
BR9509433A (pt) 1997-09-16
DK0786998T3 (da) 2002-07-15
WO1996012486A1 (en) 1996-05-02
EP0786998A1 (en) 1997-08-06
CZ287370B6 (en) 2000-11-15
PT786998E (pt) 2002-09-30
ZA958946B (en) 1996-08-20
US5891887A (en) 1999-04-06
HK1002057A1 (en) 1998-07-31
CZ125197A3 (en) 1997-07-16
KR100393365B1 (ko) 2003-12-18
NO971899L (no) 1997-04-24
AU3843195A (en) 1996-05-15
EP0786998B1 (en) 2002-03-27
ATE214926T1 (de) 2002-04-15
NO971899D0 (no) 1997-04-24
CN1170365A (zh) 1998-01-14
SK50497A3 (en) 1997-09-10
MX9703077A (es) 1997-07-31
NZ295155A (en) 2000-07-28
JPH10509697A (ja) 1998-09-22
GB9421472D0 (en) 1994-12-07
DE69526102D1 (de) 2002-05-02
BG101500A (en) 1998-01-30
NO312055B1 (no) 2002-03-11
KR970706816A (ko) 1997-12-01
CN1085529C (zh) 2002-05-29

Similar Documents

Publication Publication Date Title
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
KR960700059A (ko) 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes)
PT840601E (pt) Thip para o tratamento de desordens do sono
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
PT946162E (pt) Utilizacao de derivados do p-aminofenol para a preparacao de composicoes farmaceuticas uteis no tratamento de doencas neurodegenerativas
ES2173977T3 (es) Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.
DK0738147T3 (da) Anvendelse af riluzol ved behandling af mitochondriesygdomme
SE8903529D0 (sv) Medical use
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
KR930703013A (ko) 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제
DK0642338T3 (da) Anvendelse af (E)-2-(p-fluorphenethyl)-3-fluorallylamin i behandlingen af Alzheimers sygdom
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono
Magdy M et al. < A> new treatment modality proposed for the management of denture sore mouth

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 786998

Country of ref document: ES